Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 4, 2015, Pages 163.e15-163.e23

  Cantiello, Francesco ^a   Russo, Giorgio Ivan ^b   Ferro, Matteo ^c   Cicione, Antonio ^a   Cimino, Sebastiano ^b   Favilla, Vincenzo ^b   Perdonà, Sisto ^d   Bottero, Danilo ^c   Terracciano, Daniela ^e   De Cobelli, Ottavio ^c   Morgia, Giuseppe ^b   Damiano, Rocco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Active surveillance; PCA3; PHI; Prognostic accuracy; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE CANCER ANTIGEN 3; TUMOR ANTIGEN; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BODY MASS; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATECTOMY; SEMINAL VESICLE; TUMOR VOLUME; AREA UNDER THE CURVE; COHORT ANALYSIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

AGED; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BIOMARKERS, TUMOR; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84933278304     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.12.002     Document Type: Article

References (30)

1. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014, 10.1016/S0140-6736(14)60525-0.
2. Hugosson J., Carlsson S., Aus G., et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010, 11:725-732.
3. Loeb S., Bjurlin M.A., Nicholson J., et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014, 65:1046-1055.
4. Loeb S., Gonzalez C.M., Roehl K.A., et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 2006, 175:902-906.
5. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008, 179:1804-1809. [discussion 9-10].
6. Whitman E.J., Groskopf J., Ali A., et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008, 180:1975-1978. [discussion 8-9].
7. Auprich M., Chun F.K., Ward J.F., et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011, 59:96-105.
8. Durand X., Xylinas E., Radulescu C., et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012, 110:43-49.
9. Ploussard G., Durand X., Xylinas E., et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011, 59:422-429.
10. Hessels D., van Gils M.P., van Hooij O., et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010, 70:10-16.
11. van Gils M.P., Hessels D., Hulsbergen-van de Kaa C.A., et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008, 68:1215-1222.
12. Stephan C., Vincendeau S., Houlgatte A., Cammann H., Jung K., Semjonow A. Multicenter evaluation of [-2]proprostate-specific antigen and the Prostate Health Index for detecting prostate cancer. Clin Chem 2013, 59:306-314.
13. Lazzeri M., Haese A., de la Taille A., et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10ng/ml: a multicentric European study. Eur Urol 2013, 63:986-994.
14. Guazzoni G., Lazzeri M., Nava L., et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012, 61:455-466.
15. Catalona W.J., Partin A.W., Sanda M.G., et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0ng/ml prostate specific antigen range. J Urol. 2011, 185:1650-1655.
16. Semjonow A., Kopke T., Eltze E., Pepping-Schefers B., Burgel H., Darte C. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010, 43:926-928.
17. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006, 52:1089-1095.
18. Van der Kwast T.H., Amin M.B., Billis A., et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011, 24:16-25.
19. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005, 29:1228-1242.
20. Chen M.E., Johnston D., Reyes A.O., Soto C.P., Babaian R.J., Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 2003, 27:1291-1301.
21. Epstein J.I., Walsh P.C., Carmichael M., Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J Am Med Assoc 1994, 271:368-374.
22. Roemeling S., Roobol M.J., Postma R., et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 2006, 50:475-482.
23. Russo G.I., Cimino S., Castelli T., et al. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria. Urol Oncol 2014, 32:291-296.
24. Tosoian J.J., Loeb S., Feng Z., et al. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 2012, 188:1131-1136.
25. Hirama H., Sugimoto M., Ito K., Shiraishi T., Kakehi Y. The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 2014, 140:257-263.
26. Isharwal S., Makarov D.V., Sokoll L.J., et al. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011, 77:763.e1-763.e6.
27. Tosoian J.J., Loeb S., Kettermann A., et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010, 183:534-538.
28. Giannarini G., Scott C.A., Moro U., Pertoldi B., Beltrami C.A., Selli C. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer?. Urol Oncol 2008, 26:353-360.
29. O'Brien M.F., Cronin A.M., Fearn P.A., et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009, 27:3591-3597.
30. Ferro M., Bruzzese D., Perdonà S., et al. Prostate Health Index (PHI) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10ng/ml. Plos One 2013, 10.1371/journal.pone.0067687.